scholarly journals Histological Peripheral Margins and Recurrence of Melanoma In Situ Treated with Wide Local Excision

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Francisco S. Moura ◽  
Lucy E. Homer ◽  
Stuart W. McKirdy

Background. The incidence of melanoma in situ (MIS) is increasing faster compared to invasive melanoma. Despite varying international practice, a minimum of 5 mm surgical excision margin is currently recommended in the UK. There is no clear guidance on the minimum histological peripheral clearance margins. Aim. This study compares the histological peripheral clearance margins of MIS using wide local excision (WLE) to the rate of recurrence and progression to invasive disease. Methods. A retrospective single-center review was performed over a 5-year period. Inclusion criteria consisted of MIS diagnosis, ≥16 years of age, and treatment with WLE with curative intent. Those patients with a recurrence of a previous MIS or with a reported focus of invasion/regression were also included. Clinicopathological data and follow-up were recorded. Results. 167 MIS were identified in 155 patients, 80% of which were lentigo maligna subtype. Of patients with completely excised MIS on histology (>0 mm), 9% had recurrence with a median time to recurrence of 36 months. Three (1.8%) cases recurred as invasive disease. Age, MIS site, MIS subtype, and histological evidence of foci of invasion/regression did not predict recurrence nor progression to invasive disease ( p > 0.05 ). The recurrence rate of MIS with a histological excision margin ≤3.0 mm was 13% compared to 3% in those with histology margins of >3.0 mm ( p = 0.049 ). Conclusion. A histological peripheral clearance of at least 3.0 mm is advocated to achieve lower recurrence rates. The follow-up duration should be reviewed due to the median recurrence occurring at 36 months in our cohort. Cumulative work on MIS needs to be collated and completed in a large multicenter study with a long follow-up period.

2017 ◽  
Vol 153 (5) ◽  
pp. 436 ◽  
Author(s):  
Adi Nosrati ◽  
Jacqueline G. Berliner ◽  
Shilpa Goel ◽  
Joseph McGuire ◽  
Vera Morhenn ◽  
...  

2017 ◽  
Vol 27 (4) ◽  
pp. 791-793 ◽  
Author(s):  
Raghava Parashurama ◽  
Vivek Nama ◽  
Richard Hutson

BackgroundExtramammary Paget’s disease is a rare condition, and the vulva is a common site for it to occur. Despite this, there is a paucity of literature on Paget’s disease of the vulva (VPD). A Cochrane meta-analysis could not draw any conclusions on interventions in VPD. Our aim was to review our practice and improve further management of VPD in our center.MethodsWe reviewed all the cases presented to Leeds Gynaecological Oncology Centre between 1988 and 2016. All cases identified in this interval were followed up until April 2016. All case notes and electronic patient data were retrieved to collate the data.ResultsWe identified 18 cases of VPD. The median age at presentation was 76.9 years. Primary surgery was used in 18 cases. Eight patients had wide local excision with graft reconstruction. Ten women had wide local excision with primary reconstruction. Margins were negative in 27% of the excisions. Sixty percent of patients with clear surgical margins had a recurrence, and 69% of patients with positive margins had a recurrence; there was no statistical difference between the 2 groups for recurrence (P > 0.05). Fifty-eight percent of patients who had recurrence had coexisting malignancy. Logistic regression showed no correlation of recurrence rates due to either age, margin status, or coexisting malignancies.ConclusionsPaget’s disease of the vulva is a rare condition. Our experience indicates that most cases may be amenable to surgical treatment at first presentation. Negative margin status does not reduce the chance of recurrence, and hence patients should be under follow-up for life. The benefit of radical surgery in the absence of reduced recurrences, based on margin status, is questionable. Radiotherapy and imiquimod are options for extensive lesions or recurrent settings. Coexisting malignancies are associated with VPD.


1993 ◽  
Vol 60 (4) ◽  
pp. 345-348
Author(s):  
V. Serretta ◽  
S. Piazza ◽  
C. Pavone ◽  
G. Corselli ◽  
B. Piazza ◽  
...  

The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.


Urology ◽  
2020 ◽  
Vol 141 ◽  
pp. e51-e52
Author(s):  
Kevin Krughoff ◽  
Amichai Kilchevksy ◽  
Wayne Stadelmann ◽  
Timothy Gorman ◽  
Ramiro Madden-Fuentes

Sign in / Sign up

Export Citation Format

Share Document